AtriCure Inc.  

(Public, NASDAQ:ATRC)   Watch this stock  
Find more results for ATRC
15.31
+0.07 (0.46%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.00 - 15.32
52 week 13.44 - 28.15
Open 15.28
Vol / Avg. 0.00/198,208.00
Mkt cap 509.45M
P/E     -
Div/yield     -
EPS -1.07
Shares 33.12M
Beta 0.91
Inst. own 81%
Aug 10, 2016
AtriCure Inc at Canaccord Genuity Growth Conference - 1:30PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 AtriCure Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 AtriCure Inc Earnings Release - 4:00PM EDT - Add to calendar
May 25, 2016
AtriCure Inc Annual Shareholders Meeting
May 23, 2016
AtriCure Inc at UBS Global Healthcare Conference
May 19, 2016
AtriCure Inc Annual Shareholders Meeting (Estimated)
Apr 28, 2016
Q1 2016 AtriCure Inc Earnings Call - Webcast
Apr 28, 2016
Q1 2016 AtriCure Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -27.06% -20.97%
Operating margin -26.21% -20.59%
EBITD margin - -15.75%
Return on average assets -14.59% -12.61%
Return on average equity -21.21% -17.05%
Employees 430 -
CDP Score - -

Address

7555 Innovation Way
MASON, OH 45040-9695
United States - Map
+1-513-7554100 (Phone)
+1-513-7554567 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company's segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.

Officers and directors

Richard M. Johnston Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael H. Carrel President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
M. Andrew Wade CPA Chief Financial Officer, Senior Vice President
Age: 40
Bio & Compensation  - Reuters
Douglas J. Seith Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Andrew L. Lux Ph.D. Senior Vice President - R&D, Operations and QA
Age: 63
Bio & Compensation  - Reuters
Patricia J. Kennedy Vice President, General Manager - International
Age: 54
Bio & Compensation  - Reuters
Mark A. Collar Independent Director
Age: 62
Bio & Compensation  - Reuters
Scott William Drake Independent Director
Age: 47
Bio & Compensation  - Reuters
Michael D. Hooven Independent Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elizabeth D. Krell Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters